Lyndra Therapeutics’ Innovative Dosage Form
Change the pill, not the patient
Adherence to any medication can be a difficult task. We’ve all heard “I forgot” or “I feel fine, I don’t need to take this medication”. Lyndra Therapeutics developed a new strategy to combat patient non-adherence, an oral ultra-long-acting sustained-release capsule.
How does it work?
A drug polymer matrix that consists of insoluble and hydrophobic polymer containing drug particles as a crystalline suspension is well suited to protect against dose dumping.
Inside of a coated capsule is a star shaped component composed of three elements: six drug-loaded arms, an elastomeric core, and disintegrating matrices. Each arm is composed of a blend of a polymer matrix and either a drug or inactive material. The elastomeric core allows for the dosage form to freely move around the stomach, which in turn enhances the durability of the medication. The purpose of the disintegrating matrices is to connect the arms to the core and to allow for easier passage through the intestines when it is time for the drug to be eliminated from the body.
In the pipeline
Using this ultra long lasting oral dosage form, Lyndra seeks to expand its uses. They plan to target disease states such as HIV, schizophrenia with once-weekly dosing of risperidone, and opioid use disorder with a once-weekly dosing of buprenorphine. They are also working on developing a once-monthly oral contraceptive with a grant from the Bill & Melinda Gates Foundation. Additionally, in an effort to eliminate malaria and reach large rural populations, Lyndra is developing a once-biweekly dosage of ivermectin. Lastly, to aid in reducing transplant rejection, they are working on a once-weekly anti-rejection medication.
References:
